Skip to main content
Clinical Trials/CTIS2024-511711-21-00
CTIS2024-511711-21-00
Active, Not Recruiting
Phase 1

ChemoRadiotherapy with Or Without surgery followed by consolidation Durvalumab (CROWD): a phase IV feasibility trial

Amsterdam UMC Stichting0 sites38 target enrollmentMarch 15, 2024

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Stage III non-small cell lung cancer
Sponsor
Amsterdam UMC Stichting
Enrollment
38
Status
Active, Not Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 15, 2024
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Histologically or cytologically confirmed stage III (non\-N3\) NSCLC (TNM 8th edition), before start of chemoradiotherapy, In case of suspected N2\-disease, mediastinal invasive staging (EUS, EBUS and/or mediastinoscopy) to prove N2 involvement before start of concurrent CRT is mandatory., Initial MDT recommendation for a non\-surgical treatment comprising CRT followed by durvalumab

Exclusion Criteria

  • Patients with TxN3 or M1 disease, The use of any CRT schemes other than those in ESMO recommendations (platinum doublet, 30 once\-daily fractions of 2 Gy), Patients deemed inoperable based on cardiopulmonary function tests or comorbidity

Outcomes

Primary Outcomes

Not specified

Similar Trials